Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17088067 | 0.86 | RAD52 (0.48) | RAD52RECQLDRD2PDE10AGRM5 | |
| SCHEMBL16809329 | 0.84 | RAD52 (0.49) | RAD52RECQLDRD2GRM5P2RY1 | |
| SCHEMBL22966532 | 0.82 | RAD52 (0.44) | RAD52RECQLDRD2GRM5P2RY1 | |
| SCHEMBL15596888 | 0.82 | RAD52 (0.43) | RAD52RECQLDRD2GRM5P2RY1 | |
| SCHEMBL21451957 | 0.81 | RAD52 (0.43) | RAD52RECQLPDE10AGRM5DPP4 | |
| SCHEMBL6369558 | 0.81 | RAD52 (0.69) | RAD52RECQLPDE10AGRM5HRH3 | |
| SCHEMBL16609856 | 0.79 | RAD52 (0.47) | RAD52RECQLDRD2PDE10AGRM5 | |
| SCHEMBL16609857 | 0.79 | RAD52 (0.47) | RAD52RECQLDRD2PDE10AGRM5 | |
| SCHEMBL15918533 | 0.79 | RAD52 (0.47) | RAD52RECQLPDE10AGRM5DPP4 | |
| SCHEMBL12680942 | 0.78 | RAD52 (0.53) | RAD52RECQLDRD2PDE10AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019192506-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | WO | disclosed |
| US-9540323-B2 | 7-hydroxy-indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| US-9428504-B2 | 7-hydroxy-spiropipiperidine indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-17 | — | — | US | disclosed |
| US-20150166538-A1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY11, P2RY2 | RAD52 4386/4885RECQL 1766/4885DRD2 675/4885 |
| US-20150166538-A1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY2, P2RY11 | RAD52 3512/4885RECQL 915/4885DRD2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.